Patients with hypertriglyceridemia, treated with AKCEA-APOCIII-LRx, have experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic lipoproteins
The phase 2 study AKCEA-APOCIII-LRx met primary and key secondary endpoints with significant reductions in triglyceride ( TG ) and apoC-III levels, and a favorable safety and tolerability profile in t ...
Durable and potent LDL-cholesterol reduction with Inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of Inclisiran, a first-in-class investigational treatment for hyperlipidemia in adul ...
Medications associated with risk of developing osteoporosis
The purpose of a study was to evaluate the development in the use of medications associated with an increased risk of developing osteoporosis over the time period from 1999 to 2016. Researchers hav ...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated statins, who had completed one of four phas ...
Postmenopausal women aged 80 years or older with osteoporosis: effects of Abaloparatide on bone mineral density and risk of fracture
Advanced age is an important risk factor for fracture. The ACTIVE ( Abaloparatide Comparator Trial In Vertebral Endpoints ) trial has shown that subcutaneous Abaloparatide ( Tymlos ) increased bone mi ...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled in the open-label extension ( OLE ) study, ODY ...
Osteoporosis: combination therapy of anabolic agents and bisphosphonates improves bone mineral density
A study aimed to determine whether the concomitant combination therapy of anabolic agents and bisphosphonates produces more effects on bone mineral density ( BMD ) than anabolic agents alone in patien ...
Metabolic disease, particularly type 2 diabetes mellitus, is correlated with having bacteria that penetrate the mucus lining of the colon
In humans, developing metabolic disease, particularly type 2 diabetes, is correlated with having bacteria that penetrate the mucus lining of the colon. The findings, which provide insight on how pe ...
Obesity in adolescents significantly increases risk of heart disease regardless of ethnicity
A new study published today in BMJ Open has found a link between obesity in adolescents and their risk of developing heart disease in early adulthood, regardless of ethnicity. People of South Asian ...
Poor sleep quality may be associated with osteoporosis
The aim of the present study was to investigate the impact of sleep on osteoporosis. The study used a baseline examination of the Hiroshima Sleep and Healthcare study, which was a cross-sectional a ...
Dietary Magnesium associated with reduced risk of heart disease, stroke and type-2 diabetes mellitus
A diet rich in Magnesium may reduce the risk of diseases including heart disease ( heart failure ), stroke and type-2 diabetes mellitus according to a new meta-analysis published in the open access jo ...
GLAGOV trial: lowering LDL cholesterol with Evolocumab, a PCSK9 inhibitor, impacts underlying atherosclerotic disease on top of optimized statin therapy
The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound ) trial evaluating the effect of Evolocumab ( Repatha ) on coronary artery dis ...
Wrist circumference is a practical tool for assessment of metabolic risk in overweight-obese subjects but not as marker of advanced atherosclerosis
Body circumferences have been proposed as potential anthropometric measures for the assessment of cardiometabolic risk as they are independently associated with insulin resistance and diabetes. Th ...
Repatha Pushtronex System, a single monthly injection for PCSK9 inhibitor, approved by FDA
The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor with prefilled cartridge ), a new, monthly single-dose administration option. The ...
Diet that mimics fasting may also reduce multiple sclerosis symptoms
Evidence is mounting that a diet mimicking the effects of fasting has health benefits beyond weight loss, with a new study indicating that it may reduce symptoms of multiple sclerosis. Researchers di ...
